Display options
Cite
Chai D, Wang G, Zhou Z, et al. Insulin Increases Sestrin 2 Content by Reducing Its Degradation through the PI 3 K/mTOR Signaling Pathway. Int J Endocrinol. 2015;2015:505849doi: 10.1155/2015/505849.
Chai, D., Wang, G., Zhou, Z., Yang, H., & Yu, Z. (2015). Insulin Increases Sestrin 2 Content by Reducing Its Degradation through the PI 3 K/mTOR Signaling Pathway. International journal of endocrinology, 2015505849. https://doi.org/10.1155/2015/505849
Chai, Dandan, et al. "Insulin Increases Sestrin 2 Content by Reducing Its Degradation through the PI 3 K/mTOR Signaling Pathway." International journal of endocrinology vol. 2015 (2015): 505849. doi: https://doi.org/10.1155/2015/505849
Chai D, Wang G, Zhou Z, Yang H, Yu Z. Insulin Increases Sestrin 2 Content by Reducing Its Degradation through the PI 3 K/mTOR Signaling Pathway. Int J Endocrinol. 2015;2015:505849. doi: 10.1155/2015/505849. Epub 2015 Feb 22. PMID: 25792980; PMCID: PMC4352509.
Copy Download .nbib Format: NLM
Share it on

Int J Endocrinol. 2015;2015:505849. doi: 10.1155/2015/505849. Epub 2015 Feb 22.

Insulin Increases Sestrin 2 Content by Reducing Its Degradation through the PI 3 K/mTOR Signaling Pathway.

International journal of endocrinology

Dandan Chai, Guoyu Wang, Ziyu Zhou, Hanyan Yang, Zhiwen Yu

Affiliations

  1. Fujian Key Laboratory of Chinese Materia Medica, Biomedical Drug Research and Development Center, Fujian University of Traditional Chinese Medicine, Fuzhou 350108, China.
  2. Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Department of Nutrition, School of Public Health, Sun Yat-Sen University, Guangzhou 510080, China.

PMID: 25792980 PMCID: PMC4352509 DOI: 10.1155/2015/505849

Abstract

Sestrin (SESN) is known as a cysteine sulfinic acid reductase. Recently, nonredox functions of SESN in metabolic regulation and antitumor property have been recognized. While mechanisms underlying the expression of SESN are not fully understood. Here we report that insulin markedly increased SESN2 level in HepG2 cells through mTOR activation. To determine whether insulin affects SESN2 degradation, we assessed SESN2 turnover by applying the protein synthesis inhibitor, cycloheximide (CHX), and found that following insulin treatment SESN2 protein levels were reduced significantly slower than non-insulin-treated cells. Furthermore, the proteasomal inhibitor, MG132, dramatically increased SESN2 protein and its ubiquitination level while in the presence of MG132 insulin did not further increase SESN2 content, suggesting that insulin increases SESN2 content mainly via inhibiting its proteasomal degradation. We then explored the potential feedback role of SESN2 in insulin signaling by SESN2 siRNA knockdown in HepG2 cells. Following SESN2 knockdown insulin-stimulated PKB phosphorylation was enhanced and accompanied by reduced PTEN content. Taken together, our study suggests that insulin upregulates SESN2 content via the PI3K/mTOR signaling pathway and this effect is attributed to decreased SESN2 degradation. Furthermore, SESN2 via modulating PTEN plays a negative feedback role in insulin signaling.

References

  1. Nat Rev Mol Cell Biol. 2006 Feb;7(2):85-96 - PubMed
  2. Antioxid Redox Signal. 2013 Jan 1;18(1):36-50 - PubMed
  3. Antioxid Redox Signal. 2009 Apr;11(4):739-45 - PubMed
  4. Cell Metab. 2012 Sep 5;16(3):311-21 - PubMed
  5. Biochim Biophys Acta. 2014 Dec;1846(2):638-54 - PubMed
  6. PLoS One. 2013 Jul 05;8(7):e68498 - PubMed
  7. PLoS One. 2012;7(2):e32035 - PubMed
  8. Science. 2010 Mar 5;327(5970):1223-8 - PubMed
  9. Cell Metab. 2008 Sep;8(3):184-5 - PubMed
  10. Cancer Res. 2007 May 15;67(10):4671-8 - PubMed
  11. Proc Natl Acad Sci U S A. 1994 Oct 25;91(22):10640-4 - PubMed
  12. J Biol Chem. 2014 Feb 14;289(7):4083-94 - PubMed
  13. Diabetologia. 2011 Apr;54(4):922-34 - PubMed
  14. Am J Physiol Renal Physiol. 2013 Aug 15;305(4):F495-509 - PubMed
  15. J Vis Exp. 2012 Jun 29;(64):null - PubMed
  16. Endocr Rev. 2006 May;27(3):242-59 - PubMed
  17. Science. 2004 Apr 23;304(5670):596-600 - PubMed
  18. Adv Exp Med Biol. 2015;815:173-84 - PubMed
  19. Cell Death Differ. 2013 Apr;20(4):611-9 - PubMed
  20. Cell Metab. 2013 Dec 3;18(6):792-801 - PubMed
  21. Am J Physiol Endocrinol Metab. 2013 Dec 1;305(11):E1408-14 - PubMed
  22. Cell. 2008 Aug 8;134(3):451-60 - PubMed
  23. PLoS One. 2012;7(1):e28784 - PubMed

Publication Types